Akut Kas Güçsüzlüğü İle Gelen Çocuk Hastaya Yaklaşım

Naqvi U, Sherman AL. Muscle strength grading. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Aug 28 [cited 2023 Oct 1]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK436008/

Williams M. Manual muscle testing, development and current use. Phys Ther Rev. 1956;36(12):797–805.

Wintz MM. Variations in current manual muscle testing. Phys Ther Rev. 1959;39(7):466–75.

Genc B, Gozutok O, Ozdinler PH. Complexity of Generating Mouse Models to Study the Upper Motor Neurons: Let Us Shift Focus from Mice to Neurons. Int J Mol Sci. 2019;20(16):3848.

Zayia LC, Tadi P. Neuroanatomy, motor neuron. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Oct 1]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554616/

Diaz E, Morales H. Spinal Cord Anatomy and Clinical Syndromes. Semin Ultrasound CT MR. 2016;37(5):360–71.

Emos MC, Agarwal S. Neuroanatomy, Upper Motor Neuron Lesion. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.

Emos MC, Rosner J. Neuroanatomy, Upper Motor Nerve Signs. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.

Stifani N. Motor neurons and the generation of spinal motor neuron diversity. Front Cell Neurosci. 2014;8:293.

de Carvalho M, Swash M. Lower motor neuron dysfunction in ALS. Clin Neurophysiol. 2016;127(7):2670–81.

Héroux ME. Tap, tap, who's there? It's localized muscle activity elicited by the human stretch reflex. J Physiol. 2017;595(14):4575.

Mayer NH, Esquenazi A. Muscle overactivity and movement dysfunction in the upper motoneuron syndrome. Phys Med Rehabil Clin N Am. 2003;14(4):855–83.

Rhee PC. Surgical Management of Upper Extremity Deformities in Patients With Upper Motor Neuron Syndrome. J Hand Surg Am. 2019;44(3):223–35.

Askarova AE, Zhurkabayeva BD. Hemorrhagic stroke in children. J Cent Nerv Syst Dis. 2024;16.

Khalaf A, Iv M, Fullerton H, Wintermark M. Pediatric Stroke Imaging. Pediatr Neurol. 2018;86:5–18.

Klučka J, Klabusayová E, Musilová T, et al. Pediatric Patient with Ischemic Stroke: Initial Approach and Early Management. Children (Basel). 2021;8(8):649.

Ferriero DM, Fullerton HJ, Bernard TJ, et al. Management of Stroke in Neonates and Children: A Scientific Statement From the American Heart Association/American Stroke Association. Stroke. 2019;50(3):e51–e96.

Jeong G, Lim BC, Chae JH. Pediatric Stroke. J Korean Neurosurg Soc. 2015;57(6):396–400.

Andrade A, Yau I, Moharir M. Current concepts in pediatric stroke. Indian J Pediatr. 2015;82(2):179–88.

deVeber GA, Kirton A, Booth FA, et al. Epidemiology and Outcomes of Arterial Ischemic Stroke in Children: The Canadian Pediatric Ischemic Stroke Registry. Pediatr Neurol. 2017;69:58–70.

Elbers J, Wainwright MS, Amlie-Lefond C. The Pediatric Stroke Code: Early Management of the Child with Stroke. J Pediatr. 2015;167(1):19–24.e4.

Lehman LL, Khoury JC, Taylor JM, et al. Pediatric Stroke Rates Over 17 Years: Report From a Population-Based Study. J Child Neurol. 2018;33(7):463–7.

Ichord RN, Bastian R, Abraham L, et al. Interrater reliability of the Pediatric National Institutes of Health Stroke Scale (PedNIHSS) in a multicenter study. Stroke. 2011;42(3):613–7.

Sträter R, Kurnik K, Heller C, Schobess R, Luigs P, Nowak-Göttl U. Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study. Stroke. 2001;32(11):2554–8.

Fullerton HJ, Wu YW, Sidney S, Johnston SC. Risk of recurrent childhood arterial ischemic stroke in a population-based cohort: the importance of cerebrovascular imaging. Pediatrics. 2007;119(3):495–501.

Fullerton HJ, Wintermark M, Hills NK, et al. Risk of Recurrent Arterial Ischemic Stroke in Childhood: A Prospective International Study. Stroke. 2016;47(1):53–9.

Beslow LA, Smith SE, Vossough A, et al. Hemorrhagic transformation of childhood arterial ischemic stroke. Stroke. 2011;42(4):941–6.

Pavone P, Pettoello-Mantovano M, Le Pira A, et al. Acute disseminated encephalomyelitis: a long-term prospective study and meta-analysis. Neuropediatrics. 2010;41(6):246–55.

Absoud M, Lim MJ, Chong WK, et al. Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features. Mult Scler. 2013;19(1):76–86.

Murthy JM. Acute disseminated encephalomyelitis. Neurol India. 2002;50(3):238–43.

Singh RR, Sedani S, Lim M, et al. RANBP2 mutation and acute necrotizing encephalopathy: 2 cases and a literature review of the expanding clinico-radiological phenotype. Eur J Paediatr Neurol. 2015;19(2):106–13.

Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler. 2013;19(10):1261–7.

Wang C, Narayan R, Greenberg B. Anti-Myelin Oligodendrocyte Glycoprotein Antibody Associated With Gray Matter Predominant Transverse Myelitis Mimicking Acute Flaccid Myelitis: A Presentation of Two Cases. Pediatr Neurol. 2018;86:42–5.

Dubey D, Pittock SJ, Krecke KN, et al. Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. JAMA Neurol. 2019;76(3):301–9.

Franciotta D, Columba-Cabezas S, Andreoni L, et al. Oligoclonal IgG band patterns in inflammatory demyelinating human and mouse diseases. J Neuroimmunol. 2008;200(1-2):125–8.

Oliveira LM, Apóstolos-Pereira SL, Pitombeira MS, et al. Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis. Mult Scler. 2019;25(14):1907–14.

Masoud M, Prange L, Wuchich J, Hunanyan A, Mikati MA. Diagnosis and Treatment of Alternating Hemiplegia of Childhood. Curr Treat Options Neurol. 2017;19(2):8.

Rosewich H, Sweney MT, DeBrosse S, et al. Research conference summary from the 2014 International Task Force on ATP1A3-Related Disorders. Neurol Genet. 2017;3(2):e139.

Rosewich H, Ohlenbusch A, Huppke P, et al. The expanding clinical and genetic spectrum of ATP1A3-related disorders. Neurology. 2014;82(11):945–55.

Jasien JM, Bonner M, D'alli R, et al. Cognitive, adaptive, and behavioral profiles and management of alternating hemiplegia of childhood. Dev Med Child Neurol. 2019;61(5):547–54.

Carecchio M, Zorzi G, Ragona F, Zibordi F, Nardocci N. ATP1A3-related disorders: An update. Eur J Paediatr Neurol. 2018;22(2):257–63.

Sweney MT, Newcomb TM, Swoboda KJ. The expanding spectrum of neurological phenotypes in children with ATP1A3 mutations, Alternating Hemiplegia of Childhood, Rapid-onset Dystonia-Parkinsonism, CAPOS and beyond. Pediatr Neurol. 2015;52(1):56–64.

Brashear A, Sweadner KJ, Cook JF, Swoboda KJ, Ozelius L. ATP1A3-Related Neurologic Disorders. In: Adam MP, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 2008.

Panagiotakaki E, De Grandis E, Stagnaro M, et al. Clinical profile of patients with ATP1A3 mutations in Alternating Hemiplegia of Childhood—a study of 155 patients. Orphanet J Rare Dis. 2015;10:123.

Neville BG, Ninan M. The treatment and management of alternating hemiplegia of childhood. Dev Med Child Neurol. 2007;49(10):777–80.

Lagman-Bartolome AM, Lay C. Pediatric migraine variants: a review of epidemiology, diagnosis, treatment, and outcome. Curr Neurol Neurosci Rep. 2015;15(6):34.

Tenney JR, Schapiro MB. Child neurology: alternating hemiplegia of childhood. Neurology. 2010;74(14):e57–9.

Pereira P, Guerreiro A, Fonseca M, et al. A Distinct Phenotype in a Novel ATP1A3 Mutation: Connecting the Two Ends of a Spectrum. Mov Disord Clin Pract. 2015;3(4):398–401.

Mikati MA, Maguire H, Barlow CF, et al. A syndrome of autosomal dominant alternating hemiplegia: clinical presentation mimicking intractable epilepsy; chromosomal studies; and physiologic investigations. Neurology. 1992;42(12):2251–7.

Mikati MA, Kramer U, Zupanc ML, Shanahan RJ. Alternating hemiplegia of childhood: clinical manifestations and long-term outcome. Pediatr Neurol. 2000;23(2):134–41.

Pledger GW, Sackellares JC, Treiman DM, et al. Flunarizine for treatment of partial seizures: results of a concentration-controlled trial. Neurology. 1994;44(10):1830–6.

Chi LY, Zhao XH, Liu XW, Jiang WJ, Chi ZF, Wang SJ. Alternating hemiplegia of childhood in Chinese following long-term treatment with flunarizine or topiramate. Int J Neurosci. 2012;122(9):506–10.

International Headache Society (IHS). The International Classification of Headache Disorders, 3rd ed.; International Headache Society: London, UK; 2018.

Toldo I, Brunello F, Morao V, et al. First Attack and Clinical Presentation of Hemiplegic Migraine in Pediatric Age: A Multicenter Retrospective Study and Literature Review. Front Neurol. 2019;10:1079.

Hiekkala ME, Vuola P, Artto V, et al. The Contribution of CACNA1A, ATP1A2 and SCN1A Mutations in Hemiplegic Migraine: A Clinical and Genetic Study in Finnish Migraine Families. Cephalalgia. 2018;38(13):1849–63.

Cuenca-León E, Corominas R, Fernàndez-Castillo N, et al. Genetic Analysis of 27 Spanish Patients with Hemiplegic Migraine, Basilar-Type Migraine and Childhood Periodic Syndromes. Cephalalgia. 2008;28(10):1039–47.

Eriksen MK, Thomsen LL, Olesen J. Implications of Clinical Subtypes of Migraine with Aura. Headache. 2006;46(2):286–97.

Thomsen LL, Eriksen MK, Roemer SF, et al. A Population-Based Study of Familial Hemiplegic Migraine Suggests Revised Diagnostic Criteria. Brain. 2002;125(Pt 6):1379–91.

Thomsen LL, Ostergaard E, Olesen J, Russell MB. Evidence for a Separate Type of Migraine with Aura Sporadic Hemiplegic Migraine. Neurology. 2003;60(4):595–601.

Barros J, Ferreira A, Brandão AF, et al. Familial Hemiplegic Migraine Due to L263V SCN1A Mutation: Discordance for Epilepsy between Two Kindreds from Douro Valley. Cephalalgia. 2014;34(12):1015–20.

Pelzer N, Haan J, Stam AH, et al. Clinical Spectrum of Hemiplegic Migraine and Chances of Finding a Pathogenic Mutation. Neurology. 2018;90(7):e575–82.

Ducros A, Denier C, Joutel A, et al. The clinical spectrum of familial hemiplegic migraine associated with mutations in a neuronal calcium channel. N Engl J Med. 2001;345(1):17–24.

Marconi R, De Fusco M, Aridon P, et al. Familial Hemiplegic Migraine Type 2 Is Linked to 0.9Mb Region on Chromosome 1q23. Ann Neurol. 2003;53(3):376–81.

Jurkat-Rott K, Freilinger T, Dreier JP, et al. Variability of Familial Hemiplegic Migraine with Novel A1A2 Na/K-ATPase Variants. Neurology. 2004;62(10):1857–61.

Wolf VL, Lupo PJ, Lotze TE. Pediatric acute transverse myelitis overview and differential diagnosis. J Child Neurol. 2012;27(11):1426–36.

Banwell B, Kennedy J, Sadovnick D, et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology. 2009;72(3):232–9.

Thomas T, Branson HM, Verhey LH, et al. The demographic, clinical, and magnetic resonance imaging (MRI) features of transverse myelitis in children. J Child Neurol. 2012;27(1):11–21.

Defresne P, Hollenberg H, Husson B, et al. Acute transverse myelitis in children: clinical course and prognostic factors. J Child Neurol. 2003;18(6):401–6.

Pidcock F, Sébire G. What is acute transverse myelitis in children? In: Demyelinating disorders of the central nervous system in childhood. Cambridge: Cambridge University Press; 2011. p. 243–54.

Popa C, Popa F, Grigorean VT, et al. Vascular dysfunctions following spinal cord injury. J Med Life. 2010;3(3):275–85.

Deiva K, Absoud M, Hemingway C, et al. Acute idiopathic transverse myelitis in children: early predictors of relapse and disability. Neurology. 2015;84(4):341–9.

Pidcock FS, Krishnan C, Crawford TO, et al. Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology. 2007;68(18):1474–80.

Alper G, Petropoulou KA, Fitz CR, Kim Y. Idiopathic acute transverse myelitis in children: an analysis and discussion of MRI findings. Mult Scler. 2011;17(1):74–80.

Flanagan EP, Weinshenker BG, Krecke KN, et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol. 2015;72(1):81–7.

Meyer P, Leboucq N, Molinari N, et al. Partial acute transverse myelitis is a predictor of multiple sclerosis in children. Mult Scler. 2014;20(11):1485–93.

Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002;59(4):499–505.

Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;77(24):2128–34.

Defresne P, Meyer L, Tardieu M, et al. Efficacy of high dose steroid therapy in children with severe acute transverse myelitis. J Neurol Neurosurg Psychiatry. 2001;71(2):272–4.

Rolak LA, Rutecki P, Ashizawa T, Harati Y. Clinical features of Todd's post-epileptic paralysis. J Neurol Neurosurg Psychiatry. 1992;55(1):63–4.

Morens DM, Folkers GK, Fauci AS. Acute Flaccid Myelitis: Something Old and Something New. mBio. 2019;10(2):e00521-19.

Apostol LN, Suzuki A, Bautista A, et al. Detection of non-polio enteroviruses from 17 years of virological surveillance of acute flaccid paralysis in the Philippines. J Med Virol. 2012;84(4):624–31.

Gordon-Lipkin E, Muñoz LS, Klein JL, et al. Comparative quantitative clinical, neuroimaging, and functional profiles in children with acute flaccid myelitis at acute and convalescent stages of disease. Dev Med Child Neurol. 2019;61(3):366–75

Fatemi Y, Chakraborty R. Acute Flaccid Myelitis: A Clinical Overview for 2019. Mayo Clin Proc. 2019;94(5):875–81.

Murphy OC, Pardo CA. Acute Flaccid Myelitis: A Clinical Review. Semin Neurol. 2020;40(2):211–8.

Hopkins SE, Elrick MJ, Messacar K. Acute Flaccid Myelitis-Keys to Diagnosis, Questions About Treatment, and Future Directions. JAMA Pediatr. 2019;173(2):117–8.

Melicosta ME, Dean J, Hagen K, et al. Acute flaccid myelitis: Rehabilitation challenges and outcomes in a pediatric cohort. J Pediatr Rehabil Med. 2019;12(3):245–53.

Hopkins SE. Acute Flaccid Myelitis: Etiologic Challenges, Diagnostic and Management Considerations. Curr Treat Options Neurol. 2017;19(12):48.

Messacar K, Spence-Davizon E, Osborne C, et al. Clinical characteristics of enterovirus A71 neurological disease during an outbreak in children in Colorado, USA, in 2018: an observational cohort study. Lancet Infect Dis. 2020;20(2):230–9.

Okumura A, Mori H, Fee Chong P, et al. Serial MRI findings of acute flaccid myelitis during an outbreak of enterovirus D68 infection in Japan. Brain Dev. 2019;41(5):443–51.

Maloney JA, Mirsky DM, Messacar K, et al. MRI findings in children with acute flaccid paralysis and cranial nerve dysfunction occurring during the 2014 enterovirus D68 outbreak. AJNR Am J Neuroradiol. 2015;36(2):245–50.

Elrick MJ, Gordon-Lipkin E, Crawford TO, et al. Clinical Subpopulations in a Sample of North American Children Diagnosed With Acute Flaccid Myelitis, 2012-2016. JAMA Pediatr. 2019;173(2):134–9.

Theroux LM, Brenton JN. Acute Transverse and Flaccid Myelitis in Children. Curr Treat Options Neurol. 2019;21(12):64.

Lopez A, Lee A, Guo A, et al. Vital Signs: Surveillance for Acute Flaccid Myelitis - United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(27):608–14.

Messacar K, Schreiner TL, Van Haren K, et al. Acute flaccid myelitis: A clinical review of US cases 2012-2015. Ann Neurol. 2016;80(3):326–38.

Sejvar JJ, Lopez AS, Cortese MM, et al. Acute Flaccid Myelitis in the United States, August-December 2014: Results of Nationwide Surveillance. Clin Infect Dis. 2016;63(6):737–45.

Van Haren K, Ayscue P, Waubant E, et al. Acute Flaccid Myelitis of Unknown Etiology in California, 2012-2015. JAMA. 2015;314(24):2663–71.

Yea C, Bitnun A, Robinson J, et al. Longitudinal Outcomes in the 2014 Acute Flaccid Paralysis Cluster in Canada. J Child Neurol. 2017;32(3):301–7.

Ooi MH, Wong SC, Mohan A, et al. Identification and validation of clinical predictors for the risk of neurological involvement in children with hand, foot, and mouth disease in Sarawak. BMC Infect Dis. 2009;9:3.

Chang LY, Hsia SH, Wu CT, et al. Outcome of enterovirus 71 infections with or without stage-based management: 1998 to 2002. Pediatr Infect Dis J. 2004;23(4):327–32.

Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36(2):123–33.

Vajsar J, Fehlings D, Stephens D. Long-term outcome in children with Guillain-Barré syndrome. J Pediatr. 2003;142(3):305–9.

Roodbol J, de Wit MC, Aarsen FK, Catsman-Berrevoets CE, Jacobs BC. Long-term outcome of Guillain-Barré syndrome in children. J Peripher Nerv Syst. 2014;19(2):121–6.

Doets AY, Verboon C, van den Berg B, et al. Regional variation of Guillain-Barré syndrome. Brain. 2018;141(10):2866–77.

Rosser T, editor. Pediatric neurology: a case-based review. Philadelphia: Lippincott Williams & Wilkins; 2007.

Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717–27.

Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671–83.

Rabie M, Ashwal S, Nevo Y. Inflammatory Neuropathies. In: Swaiman KF, et al., editors. Pediatric Neurology: Principles & Practice. 6th ed. Philadelphia: Elsevier Health Sciences; 2017. p. 1086–90.

Kinali M, Beeson D, Pitt MC, et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. J Neuroimmunol. 2008;201-202:6–12.

Engel AG, Shen XM, Selcen D, Sine SM. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol. 2015;14(4):420–34.

Téllez-Zenteno JF, Hernández-Ronquillo L, Salinas V, Estanol B, da Silva O. Myasthenia gravis and pregnancy: clinical implications and neonatal outcome. BMC Musculoskelet Disord. 2004;5:42.

Namba T, Brown SB, Grob D. Neonatal myasthenia gravis: report of two cases and review of the literature. Pediatrics. 1970;45(3):488–504.

Liew WK, Kang PB. Update on juvenile myasthenia gravis. Curr Opin Pediatr. 2013;25(6):694–700.

Gadient P, Bolton J, Puri V. Juvenile myasthenia gravis: three case reports and a literature review. J Child Neurol. 2013;28(5):615–9.

Zhang X, Yang M, Xu J, et al. Clinical and serological study of myasthenia gravis in HuBei Province, China. J Neurol Neurosurg Psychiatry. 2007;78(4):386–90.

Chiu HC, Vincent A, Newsom-Davis J, Hsieh KH, Hung T. Myasthenia gravis: population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians. Neurology. 1987;37(12):1854–7.

Castro D, Derisavifard S, Anderson M, Greene M, Iannaccone S. Juvenile myasthenia gravis: a twenty-year experience. J Clin Neuromuscul Dis. 2013;14(3):95–102.

Nemet AY, Segal O, Mimouni M, Vinker S. Associated morbidity of pediatric ptosis—a large, community based case-control study. Graefes Arch Clin Exp Ophthalmol. 2014;252(9):1509–14.

Golnik KC, Pena R, Lee AG, Eggenberger ER. An ice test for the diagnosis of myasthenia gravis. Ophthalmology. 1999;106(7):1282–6.

Sethi KD, Rivner MH, Swift TR. Ice pack test for myasthenia gravis. Neurology. 1987;37(8):1383–5.

Odel JG, Winterkorn JM, Behrens MM. The sleep test for myasthenia gravis. A safe alternative to Tensilon. J Clin Neuroophthalmol. 1991;11(4):288–92.

Kubis KC, Danesh-Meyer HV, Savino PJ, Sergott RC. The ice test versus the rest test in myasthenia gravis. Ophthalmology. 2000;107(11):1995–8.

Rusyniak DE, Nañagas KA. Organophosphate poisoning. Semin Neurol. 2004;24(2):197–204.

Lee P, Tai DY. Clinical features of patients with acute organophosphate poisoning requiring intensive care. Intensive Care Med. 2001;27(4):694–9.

Wadia RS, Bhirud RH, Gulavani AV, Amin RB. Neurological manifestations of three organophosphate poisons. Indian J Med Res. 1977;66(3):460–8.

Sungur M, Güven M. Intensive care management of organophosphate insecticide poisoning. Crit Care. 2001;5(4):211–5.

De Bleecker J, Vogelaers D, Ceuterick C, Van Den Neucker K, Willems J, De Reuck J. Intermediate syndrome due to prolonged parathion poisoning. Acta Neurol Scand. 1992;86(4):421–4.

Senanayake N, Karalliedde L. Neurotoxic effects of organophosphorus insecticides. An intermediate syndrome. N Engl J Med. 1987;316(13):761–3.

Lotti M, Becker CE, Aminoff MJ. Organophosphate polyneuropathy: pathogenesis and prevention. Neurology. 1984;34(5):658–62.

Carrillo-Marquez MA. Botulism. Pediatr Rev. 2016;37(5):183–92.

Smith LD. Botulism: The organism, its toxins, the disease. Springfield (IL): Charles C Thomas; 1977.

Piña-Garza JE, Fenichel GM. Flaccid limb weakness in childhood. In: Fenichel's Clinical Pediatric Neurology: A Signs and Symptoms Approach. 7th ed. London: Elsevier; 2003. p. 174.

Rao AK, Sobel J, Chatham-Stephens K, Luquez C. Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021. MMWR Recomm Rep. 2021;70(2):1–30.

Maslanka S, Agam KR. Botulism. In: Kasper D, Fauci A, Hauser S, et al., editors. Harrison’s Principles of Internal Medicine. 19th ed. New York: McGraw-Hill Education; 2015.

Naqvi U, Sherman AL. Muscle strength grading. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Aug 28 [cited 2023 Oct 1]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK436008/

Williams M. Manual muscle testing, development and current use. Phys Ther Rev. 1956;36(12):797–805.

Wintz MM. Variations in current manual muscle testing. Phys Ther Rev. 1959;39(7):466–75.

Genc B, Gozutok O, Ozdinler PH. Complexity of Generating Mouse Models to Study the Upper Motor Neurons: Let Us Shift Focus from Mice to Neurons. Int J Mol Sci. 2019;20(16):3848.

Zayia LC, Tadi P. Neuroanatomy, motor neuron. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Oct 1]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554616/

Diaz E, Morales H. Spinal Cord Anatomy and Clinical Syndromes. Semin Ultrasound CT MR. 2016;37(5):360–71.

Emos MC, Agarwal S. Neuroanatomy, Upper Motor Neuron Lesion. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.

Emos MC, Rosner J. Neuroanatomy, Upper Motor Nerve Signs. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.

Stifani N. Motor neurons and the generation of spinal motor neuron diversity. Front Cell Neurosci. 2014;8:293.

de Carvalho M, Swash M. Lower motor neuron dysfunction in ALS. Clin Neurophysiol. 2016;127(7):2670–81.

Héroux ME. Tap, tap, who's there? It's localized muscle activity elicited by the human stretch reflex. J Physiol. 2017;595(14):4575.

Mayer NH, Esquenazi A. Muscle overactivity and movement dysfunction in the upper motoneuron syndrome. Phys Med Rehabil Clin N Am. 2003;14(4):855–83.

Rhee PC. Surgical Management of Upper Extremity Deformities in Patients With Upper Motor Neuron Syndrome. J Hand Surg Am. 2019;44(3):223–35.

Askarova AE, Zhurkabayeva BD. Hemorrhagic stroke in children. J Cent Nerv Syst Dis. 2024;16.

Khalaf A, Iv M, Fullerton H, Wintermark M. Pediatric Stroke Imaging. Pediatr Neurol. 2018;86:5–18.

Klučka J, Klabusayová E, Musilová T, et al. Pediatric Patient with Ischemic Stroke: Initial Approach and Early Management. Children (Basel). 2021;8(8):649.

Ferriero DM, Fullerton HJ, Bernard TJ, et al. Management of Stroke in Neonates and Children: A Scientific Statement From the American Heart Association/American Stroke Association. Stroke. 2019;50(3):e51–e96.

Jeong G, Lim BC, Chae JH. Pediatric Stroke. J Korean Neurosurg Soc. 2015;57(6):396–400.

Andrade A, Yau I, Moharir M. Current concepts in pediatric stroke. Indian J Pediatr. 2015;82(2):179–88.

deVeber GA, Kirton A, Booth FA, et al. Epidemiology and Outcomes of Arterial Ischemic Stroke in Children: The Canadian Pediatric Ischemic Stroke Registry. Pediatr Neurol. 2017;69:58–70.

Elbers J, Wainwright MS, Amlie-Lefond C. The Pediatric Stroke Code: Early Management of the Child with Stroke. J Pediatr. 2015;167(1):19–24.e4.

Lehman LL, Khoury JC, Taylor JM, et al. Pediatric Stroke Rates Over 17 Years: Report From a Population-Based Study. J Child Neurol. 2018;33(7):463–7.

Ichord RN, Bastian R, Abraham L, et al. Interrater reliability of the Pediatric National Institutes of Health Stroke Scale (PedNIHSS) in a multicenter study. Stroke. 2011;42(3):613–7.

Sträter R, Kurnik K, Heller C, Schobess R, Luigs P, Nowak-Göttl U. Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study. Stroke. 2001;32(11):2554–8.

Fullerton HJ, Wu YW, Sidney S, Johnston SC. Risk of recurrent childhood arterial ischemic stroke in a population-based cohort: the importance of cerebrovascular imaging. Pediatrics. 2007;119(3):495–501.

Fullerton HJ, Wintermark M, Hills NK, et al. Risk of Recurrent Arterial Ischemic Stroke in Childhood: A Prospective International Study. Stroke. 2016;47(1):53–9.

Beslow LA, Smith SE, Vossough A, et al. Hemorrhagic transformation of childhood arterial ischemic stroke. Stroke. 2011;42(4):941–6.

Pavone P, Pettoello-Mantovano M, Le Pira A, et al. Acute disseminated encephalomyelitis: a long-term prospective study and meta-analysis. Neuropediatrics. 2010;41(6):246–55.

Absoud M, Lim MJ, Chong WK, et al. Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features. Mult Scler. 2013;19(1):76–86.

Murthy JM. Acute disseminated encephalomyelitis. Neurol India. 2002;50(3):238–43.

Singh RR, Sedani S, Lim M, et al. RANBP2 mutation and acute necrotizing encephalopathy: 2 cases and a literature review of the expanding clinico-radiological phenotype. Eur J Paediatr Neurol. 2015;19(2):106–13.

Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler. 2013;19(10):1261–7.

Wang C, Narayan R, Greenberg B. Anti-Myelin Oligodendrocyte Glycoprotein Antibody Associated With Gray Matter Predominant Transverse Myelitis Mimicking Acute Flaccid Myelitis: A Presentation of Two Cases. Pediatr Neurol. 2018;86:42–5.

Dubey D, Pittock SJ, Krecke KN, et al. Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. JAMA Neurol. 2019;76(3):301–9.

Franciotta D, Columba-Cabezas S, Andreoni L, et al. Oligoclonal IgG band patterns in inflammatory demyelinating human and mouse diseases. J Neuroimmunol. 2008;200(1-2):125–8.

Oliveira LM, Apóstolos-Pereira SL, Pitombeira MS, et al. Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis. Mult Scler. 2019;25(14):1907–14.

Masoud M, Prange L, Wuchich J, Hunanyan A, Mikati MA. Diagnosis and Treatment of Alternating Hemiplegia of Childhood. Curr Treat Options Neurol. 2017;19(2):8.

Rosewich H, Sweney MT, DeBrosse S, et al. Research conference summary from the 2014 International Task Force on ATP1A3-Related Disorders. Neurol Genet. 2017;3(2):e139.

Rosewich H, Ohlenbusch A, Huppke P, et al. The expanding clinical and genetic spectrum of ATP1A3-related disorders. Neurology. 2014;82(11):945–55.

Jasien JM, Bonner M, D'alli R, et al. Cognitive, adaptive, and behavioral profiles and management of alternating hemiplegia of childhood. Dev Med Child Neurol. 2019;61(5):547–54.

Carecchio M, Zorzi G, Ragona F, Zibordi F, Nardocci N. ATP1A3-related disorders: An update. Eur J Paediatr Neurol. 2018;22(2):257–63.

Sweney MT, Newcomb TM, Swoboda KJ. The expanding spectrum of neurological phenotypes in children with ATP1A3 mutations, Alternating Hemiplegia of Childhood, Rapid-onset Dystonia-Parkinsonism, CAPOS and beyond. Pediatr Neurol. 2015;52(1):56–64.

Brashear A, Sweadner KJ, Cook JF, Swoboda KJ, Ozelius L. ATP1A3-Related Neurologic Disorders. In: Adam MP, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 2008.

Panagiotakaki E, De Grandis E, Stagnaro M, et al. Clinical profile of patients with ATP1A3 mutations in Alternating Hemiplegia of Childhood—a study of 155 patients. Orphanet J Rare Dis. 2015;10:123.

Neville BG, Ninan M. The treatment and management of alternating hemiplegia of childhood. Dev Med Child Neurol. 2007;49(10):777–80.

Lagman-Bartolome AM, Lay C. Pediatric migraine variants: a review of epidemiology, diagnosis, treatment, and outcome. Curr Neurol Neurosci Rep. 2015;15(6):34.

Tenney JR, Schapiro MB. Child neurology: alternating hemiplegia of childhood. Neurology. 2010;74(14):e57–9.

Pereira P, Guerreiro A, Fonseca M, et al. A Distinct Phenotype in a Novel ATP1A3 Mutation: Connecting the Two Ends of a Spectrum. Mov Disord Clin Pract. 2015;3(4):398–401.

Mikati MA, Maguire H, Barlow CF, et al. A syndrome of autosomal dominant alternating hemiplegia: clinical presentation mimicking intractable epilepsy; chromosomal studies; and physiologic investigations. Neurology. 1992;42(12):2251–7.

Mikati MA, Kramer U, Zupanc ML, Shanahan RJ. Alternating hemiplegia of childhood: clinical manifestations and long-term outcome. Pediatr Neurol. 2000;23(2):134–41.

Pledger GW, Sackellares JC, Treiman DM, et al. Flunarizine for treatment of partial seizures: results of a concentration-controlled trial. Neurology. 1994;44(10):1830–6.

Chi LY, Zhao XH, Liu XW, Jiang WJ, Chi ZF, Wang SJ. Alternating hemiplegia of childhood in Chinese following long-term treatment with flunarizine or topiramate. Int J Neurosci. 2012;122(9):506–10.

International Headache Society (IHS). The International Classification of Headache Disorders, 3rd ed.; International Headache Society: London, UK; 2018.

Toldo I, Brunello F, Morao V, et al. First Attack and Clinical Presentation of Hemiplegic Migraine in Pediatric Age: A Multicenter Retrospective Study and Literature Review. Front Neurol. 2019;10:1079.

Hiekkala ME, Vuola P, Artto V, et al. The Contribution of CACNA1A, ATP1A2 and SCN1A Mutations in Hemiplegic Migraine: A Clinical and Genetic Study in Finnish Migraine Families. Cephalalgia. 2018;38(13):1849–63.

Cuenca-León E, Corominas R, Fernàndez-Castillo N, et al. Genetic Analysis of 27 Spanish Patients with Hemiplegic Migraine, Basilar-Type Migraine and Childhood Periodic Syndromes. Cephalalgia. 2008;28(10):1039–47.

Eriksen MK, Thomsen LL, Olesen J. Implications of Clinical Subtypes of Migraine with Aura. Headache. 2006;46(2):286–97.

Thomsen LL, Eriksen MK, Roemer SF, et al. A Population-Based Study of Familial Hemiplegic Migraine Suggests Revised Diagnostic Criteria. Brain. 2002;125(Pt 6):1379–91.

Thomsen LL, Ostergaard E, Olesen J, Russell MB. Evidence for a Separate Type of Migraine with Aura Sporadic Hemiplegic Migraine. Neurology. 2003;60(4):595–601.

Barros J, Ferreira A, Brandão AF, et al. Familial Hemiplegic Migraine Due to L263V SCN1A Mutation: Discordance for Epilepsy between Two Kindreds from Douro Valley. Cephalalgia. 2014;34(12):1015–20.

Pelzer N, Haan J, Stam AH, et al. Clinical Spectrum of Hemiplegic Migraine and Chances of Finding a Pathogenic Mutation. Neurology. 2018;90(7):e575–82.

Ducros A, Denier C, Joutel A, et al. The clinical spectrum of familial hemiplegic migraine associated with mutations in a neuronal calcium channel. N Engl J Med. 2001;345(1):17–24.

Marconi R, De Fusco M, Aridon P, et al. Familial Hemiplegic Migraine Type 2 Is Linked to 0.9Mb Region on Chromosome 1q23. Ann Neurol. 2003;53(3):376–81.

Jurkat-Rott K, Freilinger T, Dreier JP, et al. Variability of Familial Hemiplegic Migraine with Novel A1A2 Na/K-ATPase Variants. Neurology. 2004;62(10):1857–61.

Wolf VL, Lupo PJ, Lotze TE. Pediatric acute transverse myelitis overview and differential diagnosis. J Child Neurol. 2012;27(11):1426–36.

Banwell B, Kennedy J, Sadovnick D, et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology. 2009;72(3):232–9.

Thomas T, Branson HM, Verhey LH, et al. The demographic, clinical, and magnetic resonance imaging (MRI) features of transverse myelitis in children. J Child Neurol. 2012;27(1):11–21.

Defresne P, Hollenberg H, Husson B, et al. Acute transverse myelitis in children: clinical course and prognostic factors. J Child Neurol. 2003;18(6):401–6.

Pidcock F, Sébire G. What is acute transverse myelitis in children? In: Demyelinating disorders of the central nervous system in childhood. Cambridge: Cambridge University Press; 2011. p. 243–54.

Popa C, Popa F, Grigorean VT, et al. Vascular dysfunctions following spinal cord injury. J Med Life. 2010;3(3):275–85.

Deiva K, Absoud M, Hemingway C, et al. Acute idiopathic transverse myelitis in children: early predictors of relapse and disability. Neurology. 2015;84(4):341–9.

Pidcock FS, Krishnan C, Crawford TO, et al. Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology. 2007;68(18):1474–80.

Alper G, Petropoulou KA, Fitz CR, Kim Y. Idiopathic acute transverse myelitis in children: an analysis and discussion of MRI findings. Mult Scler. 2011;17(1):74–80.

Flanagan EP, Weinshenker BG, Krecke KN, et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol. 2015;72(1):81–7.

Meyer P, Leboucq N, Molinari N, et al. Partial acute transverse myelitis is a predictor of multiple sclerosis in children. Mult Scler. 2014;20(11):1485–93.

Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002;59(4):499–505.

Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;77(24):2128–34.

Defresne P, Meyer L, Tardieu M, et al. Efficacy of high dose steroid therapy in children with severe acute transverse myelitis. J Neurol Neurosurg Psychiatry. 2001;71(2):272–4.

Rolak LA, Rutecki P, Ashizawa T, Harati Y. Clinical features of Todd's post-epileptic paralysis. J Neurol Neurosurg Psychiatry. 1992;55(1):63–4.

Morens DM, Folkers GK, Fauci AS. Acute Flaccid Myelitis: Something Old and Something New. mBio. 2019;10(2):e00521-19.

Apostol LN, Suzuki A, Bautista A, et al. Detection of non-polio enteroviruses from 17 years of virological surveillance of acute flaccid paralysis in the Philippines. J Med Virol. 2012;84(4):624–31.

Gordon-Lipkin E, Muñoz LS, Klein JL, et al. Comparative quantitative clinical, neuroimaging, and functional profiles in children with acute flaccid myelitis at acute and convalescent stages of disease. Dev Med Child Neurol. 2019;61(3):366–75

Fatemi Y, Chakraborty R. Acute Flaccid Myelitis: A Clinical Overview for 2019. Mayo Clin Proc. 2019;94(5):875–81.

Murphy OC, Pardo CA. Acute Flaccid Myelitis: A Clinical Review. Semin Neurol. 2020;40(2):211–8.

Hopkins SE, Elrick MJ, Messacar K. Acute Flaccid Myelitis-Keys to Diagnosis, Questions About Treatment, and Future Directions. JAMA Pediatr. 2019;173(2):117–8.

Melicosta ME, Dean J, Hagen K, et al. Acute flaccid myelitis: Rehabilitation challenges and outcomes in a pediatric cohort. J Pediatr Rehabil Med. 2019;12(3):245–53.

Hopkins SE. Acute Flaccid Myelitis: Etiologic Challenges, Diagnostic and Management Considerations. Curr Treat Options Neurol. 2017;19(12):48.

Messacar K, Spence-Davizon E, Osborne C, et al. Clinical characteristics of enterovirus A71 neurological disease during an outbreak in children in Colorado, USA, in 2018: an observational cohort study. Lancet Infect Dis. 2020;20(2):230–9.

Okumura A, Mori H, Fee Chong P, et al. Serial MRI findings of acute flaccid myelitis during an outbreak of enterovirus D68 infection in Japan. Brain Dev. 2019;41(5):443–51.

Maloney JA, Mirsky DM, Messacar K, et al. MRI findings in children with acute flaccid paralysis and cranial nerve dysfunction occurring during the 2014 enterovirus D68 outbreak. AJNR Am J Neuroradiol. 2015;36(2):245–50.

Elrick MJ, Gordon-Lipkin E, Crawford TO, et al. Clinical Subpopulations in a Sample of North American Children Diagnosed With Acute Flaccid Myelitis, 2012-2016. JAMA Pediatr. 2019;173(2):134–9.

Theroux LM, Brenton JN. Acute Transverse and Flaccid Myelitis in Children. Curr Treat Options Neurol. 2019;21(12):64.

Lopez A, Lee A, Guo A, et al. Vital Signs: Surveillance for Acute Flaccid Myelitis - United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(27):608–14.

Messacar K, Schreiner TL, Van Haren K, et al. Acute flaccid myelitis: A clinical review of US cases 2012-2015. Ann Neurol. 2016;80(3):326–38.

Sejvar JJ, Lopez AS, Cortese MM, et al. Acute Flaccid Myelitis in the United States, August-December 2014: Results of Nationwide Surveillance. Clin Infect Dis. 2016;63(6):737–45.

Van Haren K, Ayscue P, Waubant E, et al. Acute Flaccid Myelitis of Unknown Etiology in California, 2012-2015. JAMA. 2015;314(24):2663–71.

Yea C, Bitnun A, Robinson J, et al. Longitudinal Outcomes in the 2014 Acute Flaccid Paralysis Cluster in Canada. J Child Neurol. 2017;32(3):301–7.

Ooi MH, Wong SC, Mohan A, et al. Identification and validation of clinical predictors for the risk of neurological involvement in children with hand, foot, and mouth disease in Sarawak. BMC Infect Dis. 2009;9:3.

Chang LY, Hsia SH, Wu CT, et al. Outcome of enterovirus 71 infections with or without stage-based management: 1998 to 2002. Pediatr Infect Dis J. 2004;23(4):327–32.

Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36(2):123–33.

Vajsar J, Fehlings D, Stephens D. Long-term outcome in children with Guillain-Barré syndrome. J Pediatr. 2003;142(3):305–9.

Roodbol J, de Wit MC, Aarsen FK, Catsman-Berrevoets CE, Jacobs BC. Long-term outcome of Guillain-Barré syndrome in children. J Peripher Nerv Syst. 2014;19(2):121–6.

Doets AY, Verboon C, van den Berg B, et al. Regional variation of Guillain-Barré syndrome. Brain. 2018;141(10):2866–77.

Rosser T, editor. Pediatric neurology: a case-based review. Philadelphia: Lippincott Williams & Wilkins; 2007.

Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717–27.

Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671–83.

Rabie M, Ashwal S, Nevo Y. Inflammatory Neuropathies. In: Swaiman KF, et al., editors. Pediatric Neurology: Principles & Practice. 6th ed. Philadelphia: Elsevier Health Sciences; 2017. p. 1086–90.

Kinali M, Beeson D, Pitt MC, et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. J Neuroimmunol. 2008;201-202:6–12.

Engel AG, Shen XM, Selcen D, Sine SM. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol. 2015;14(4):420–34.

Téllez-Zenteno JF, Hernández-Ronquillo L, Salinas V, Estanol B, da Silva O. Myasthenia gravis and pregnancy: clinical implications and neonatal outcome. BMC Musculoskelet Disord. 2004;5:42.

Namba T, Brown SB, Grob D. Neonatal myasthenia gravis: report of two cases and review of the literature. Pediatrics. 1970;45(3):488–504.

Liew WK, Kang PB. Update on juvenile myasthenia gravis. Curr Opin Pediatr. 2013;25(6):694–700.

Gadient P, Bolton J, Puri V. Juvenile myasthenia gravis: three case reports and a literature review. J Child Neurol. 2013;28(5):615–9.

Zhang X, Yang M, Xu J, et al. Clinical and serological study of myasthenia gravis in HuBei Province, China. J Neurol Neurosurg Psychiatry. 2007;78(4):386–90.

Chiu HC, Vincent A, Newsom-Davis J, Hsieh KH, Hung T. Myasthenia gravis: population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians. Neurology. 1987;37(12):1854–7.

Castro D, Derisavifard S, Anderson M, Greene M, Iannaccone S. Juvenile myasthenia gravis: a twenty-year experience. J Clin Neuromuscul Dis. 2013;14(3):95–102.

Nemet AY, Segal O, Mimouni M, Vinker S. Associated morbidity of pediatric ptosis—a large, community based case-control study. Graefes Arch Clin Exp Ophthalmol. 2014;252(9):1509–14.

Golnik KC, Pena R, Lee AG, Eggenberger ER. An ice test for the diagnosis of myasthenia gravis. Ophthalmology. 1999;106(7):1282–6.

Sethi KD, Rivner MH, Swift TR. Ice pack test for myasthenia gravis. Neurology. 1987;37(8):1383–5.

Odel JG, Winterkorn JM, Behrens MM. The sleep test for myasthenia gravis. A safe alternative to Tensilon. J Clin Neuroophthalmol. 1991;11(4):288–92.

Kubis KC, Danesh-Meyer HV, Savino PJ, Sergott RC. The ice test versus the rest test in myasthenia gravis. Ophthalmology. 2000;107(11):1995–8.

Rusyniak DE, Nañagas KA. Organophosphate poisoning. Semin Neurol. 2004;24(2):197–204.

Lee P, Tai DY. Clinical features of patients with acute organophosphate poisoning requiring intensive care. Intensive Care Med. 2001;27(4):694–9.

Wadia RS, Bhirud RH, Gulavani AV, Amin RB. Neurological manifestations of three organophosphate poisons. Indian J Med Res. 1977;66(3):460–8.

Sungur M, Güven M. Intensive care management of organophosphate insecticide poisoning. Crit Care. 2001;5(4):211–5.

De Bleecker J, Vogelaers D, Ceuterick C, Van Den Neucker K, Willems J, De Reuck J. Intermediate syndrome due to prolonged parathion poisoning. Acta Neurol Scand. 1992;86(4):421–4.

Senanayake N, Karalliedde L. Neurotoxic effects of organophosphorus insecticides. An intermediate syndrome. N Engl J Med. 1987;316(13):761–3.

Lotti M, Becker CE, Aminoff MJ. Organophosphate polyneuropathy: pathogenesis and prevention. Neurology. 1984;34(5):658–62.

Carrillo-Marquez MA. Botulism. Pediatr Rev. 2016;37(5):183–92.

Smith LD. Botulism: The organism, its toxins, the disease. Springfield (IL): Charles C Thomas; 1977.

Piña-Garza JE, Fenichel GM. Flaccid limb weakness in childhood. In: Fenichel's Clinical Pediatric Neurology: A Signs and Symptoms Approach. 7th ed. London: Elsevier; 2003. p. 174.

Rao AK, Sobel J, Chatham-Stephens K, Luquez C. Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021. MMWR Recomm Rep. 2021;70(2):1–30.

Maslanka S, Agam KR. Botulism. In: Kasper D, Fauci A, Hauser S, et al., editors. Harrison’s Principles of Internal Medicine. 19th ed. New York: McGraw-Hill Education; 2015.